Compare EU & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EU | LCTX |
|---|---|---|
| Founded | 2009 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.2M | 388.6M |
| IPO Year | 2011 | 1996 |
| Metric | EU | LCTX |
|---|---|---|
| Price | $1.61 | $1.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $4.00 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 2.8M | 1.3M |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.76 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $43,155,000.00 | $14,556,000.00 |
| Revenue This Year | $212.11 | $109.40 |
| Revenue Next Year | $29.88 | N/A |
| P/E Ratio | $52.83 | ★ N/A |
| Revenue Growth | N/A | ★ 53.24 |
| 52 Week Low | $1.34 | $0.65 |
| 52 Week High | $4.19 | $2.09 |
| Indicator | EU | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.87 | 44.36 |
| Support Level | $1.34 | $1.14 |
| Resistance Level | $2.17 | $1.80 |
| Average True Range (ATR) | 0.10 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 65.00 | 55.56 |
enCore Energy Corp together with its subsidiary, is principally engaged in the acquisition, exploration, development and extraction of uranium resource properties in the United States. The Company is focused on the extraction of domestic uranium in the United States. The Company utilizes the In-Situ Recovery technology (ISR) to provide necessary fuel for the generation of clean, reliable, and carbon-free nuclear energy.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.